Introduction
Approximately 30-40% of patients with human immunodeficiency virus (HIV) infection are likely to develop malignancies during the course of their disease. With the improved survival of HIV patients, due to the better prevention and treatment of infectious complications, as well as the development of more effective antiretroviral therapies, there may be an increase of malignant tumours, in particular those nondiagnostic of AIDS.
Three malignancies are currently considered to be AIDS-defining conditions:
Kaposi's sarcoma (KS); intermediate or high-grade B-cell non-Hodgkin's lymphoma (NHL); invasive cervical cancer (ICC).
In addition, Hodgkin's disease (HD) has been increasingly described in the HIV setting with peculiar clinicopathologic features. Possible in anal, head and neck, lung and testicular carcinoma, melanoma and plasma cell myeloma have recently been reported (Spina et al., 1999 ).
Kaposi's sarcoma
The introduction of highly active antiretroviral therapy (HAART) has had a dramatic impact on the morbidity and mortality of individuals living with HIV. The incidence of KS, the most common malignancy observed in patients with HIV infection, has dropped precipitously since the introduction of HAART in 1996 (Gates and Kaplan, 2002 . In particular, since the use of protease inhibitors (PI), a 30-50% reduction of KS has been observed in both the USA and Europe. On the other hand, morbidity and mortality for KS are increasing. KS in the 1990s different from what happened at the beginning of the epidemics, occurs in more than 50% of cases in late stages of HIV infection and is characterized by an extremely aggressive clinical course. The risk of KS among male homosexuals is 5-10-fold higher in comparison with other groups of persons with other HIV-risk behaviours. In Italy and Spain, where intravenous drug user cases predominate, the proportion of patients with KS tends to be much lower than in the USA and northern Europe where homosexuals account for the majority of reported cases of AIDS .
KS is an angioproliferative disease of multifactorial origin characterized by angiogenesis, endothelial spindle-cell growth, inflammatory-cell infiltration and oedema. Recently, it has been hypothesized that KS cells may originate from a mesenchymal progenitor cell of either endothelial or monocyte-macrophage lineage (Toschi et al., 2002) . The pathogenesis of KS is better understood since 1994 (Chang et al., 1994) when Chang and Moore discovered a new human herpesvirus , also known as KS-associated herpesvirus (KSHV), strongly associated with all subtypes of KS, multicentric Castleman's disease and a rare form of B-cell lymphoma named primary effusion lymphoma (PEL). HHV-8 is a transforming virus transmitted both sexually and through body fluids such as saliva or blood, it has been detected in biopsy samples of more than 90% of KS lesions and KSHV DNA sequences have also been found in peripheral blood mononuclear cells of more than 50% of KS patients (Ablashi et al., 2002) . Viral oncogenesis (v-IL-6; v-BCL-2; v-cyclin D, G-protein-coupled receptor and antiapoptosis genes), cytokine-induced growth (b-FGF and VEGF), immunodysregulated state (immunosuppression due to HIV, organ transplantion, congenital disorders and cancer and its therapy) and HIV transactivating protein Tat (increase the proliferation of KS-derived spindle cells) represent fundamental conditions for the development of KS (Ensoli et al., 1990; Barillari et al., 1992) .
KS ranges from an indolent to an aggressive disease with significant morbidity and mortality. Typically, the disease presents with disseminated and pigmented skin lesions, in size from a few millimetres to several centimetres with a characteristic appearance ranging from pink to purple or brown often associated with oedema, lymph node and visceral involvement. The oral cavity (palate and gingiva) occurs in approximately 35% of patients at the time of initial diagnosis (Ficarra et al., 1998) . Visceral involvement occurs in over 50% of cases; any segment of gastrointestinal tract may be involved, in particular stomach and duodenum (abdominal pain, weight loss, malabsorption with diarrhoea or obstruction). Pulmonary KS (shortness of breath or cough or haemoptysis) is the second most common site of extracutaneous involvement and is the most lifethreatening form of the disease (Gill et al., 1984; Mitsuyasu, 1993) . Radiographic findings (nodular or interstitial or alveolar infiltrates, pleural effusion or isolated pulmonary nodule) are indistinguishable from those of more common opportunistic infections. Gallium and thallium scans may differentiate KS from other infectious aetiologies; in fact, KS is thallium positive and gallium negative, whereas infections are gallium positive and thallium negative (Turoglu et al., 1998) .
In the pre-HAART era, the AIDS Clinical Trials group (ACTG) devised a staging system based upon the extent of tumour (T), the status of the immune system in terms of CD4 cell count (I) and the presence of systemic illness (S). These classifications identified two different risk categories: a good risk (T0I0S0) with skin7 lung7minimal oral disease, CD44150 ml, no OI/bsymptoms and performance status (PS)470, and poor risk (T1I1S1) with oedema or ulcerations or extensive oral KS and visceral involvement, CD4o150 ml, OI and/ or B symptoms and PSo70 (Krown et al., 1997) . In the HAART era, a refiniment of ACTG staging system is needed. Nasti et al. (submitted for publication) collected epidemiological, clinical, staging and survival data from 211 patients with the diagnosis of AIDS-KS from January 1996, enrolled in two prospective Italian HIV cohort studies: the Italian Cooperative Group on AIDS and Tumors (GICAT) and the Italian Cohort of patients naı¨ve from antiretrovirals (ICONA). In the multivariate analysis, only the combination of poor tumour stage (T1) and poor systemic disease (S1) risk identifies patients with unfavourable prognosis, while CD4 level does not seem to provide prognostic information. The median survival for patients with T1S1 was significantly lower (38 months) compared to the median survival for patients with T0S0, T1S0 and T0S1 (good risk).
The pace of KS is quite variable, ranging from a very indolent process requiring little, if any, therapy to a rapidly progressive disease leading to patient demise (Levine and Tulpule, 2003) . Treatment decisions must be made taking into consideration the extent and the rate of tumour growth, patient's symptoms, immune system conditions and concurrent complications of HIV infection. The main problems in the treatment of KS are represented by the short duration of response despite a remarkable percentage of complete remissions (CRs) obtained with standard chemotherapy (CT), the high incidence of opportunistic infections during and after CT and the reduced haematological tolerance to conventional doses of CT.
Localized KS cutaneous lesions are treated with local radiation (20-70% complete response rate with mucositis and tissue fibrosis), HAART alitretinoid gel applied to affected areas two to four times daily, and surgical excision (Stelzer and Griffin, 1993; Conant, 1999) .
Systemic CT is reserved for patients who do not respond to HAART and/or with widespread, symptomatic, rapidly progressive, life-threatening disease and in particular with visceral involvement. Several singleagent therapies have been reported to be active in AIDSrelated KS including the vinca alkaloids (vincristine, vinblastine and vinorelbine), epipodophilotoxins (etoposide), anthracyclines (adriamycin and epirubicin), bleomycin and taxol. The overall response rate ranges from 10 to 76%, although most have been partial responses. In the early 1990s, a combination of bleomycin and vincristine, either combined or not with doxorubicin (ABV or BV), every 2 weeks was the standard therapy for rapidly progressive mucocutaneous or visceral disease with 25-88% overall response rate (ABV) and significant myelotoxicity. The liposomal anthracyclines are now considered as first-line therapy in the treatment of patients with advanced AIDS-KS. In the liposomal preparation, doxorubicin or daunorubicin have been entrapped into small unilamellar vescicles with a prolonged half-life and an increased accumulation in KS tissues. In randomized phase III studies in KS, both liposomal daunorubicin (40 mg/m 2 i.v. every 2 weeks) and doxorubicin (20 mg/m 2 i.v. every 2 weeks) as single agents had activity, respectively, equivalent or superior to combinations ABV or BV with substantially reduced toxicity and an overall response rate of 46% (Kaplan et al., 1986; Gill et al., 1996; Tavio et al., 1996) . Paclitaxel, at a dose of 135 mg/m 2 given every 3 weeks as a 3 h infusion, is considered the treatment of choice after failure of first-line chemotherapy with 59-71% response rate and bone marrow suppression, peripheral neuropathy, renal disfunction (Saville et al., 1995) . Immunosuppression is a major problem in patients treated with cytotoxic chemotherapy and because of immunodepression, patients may develop OI. The use of recombinant haematopoietic growth factors to support KS patients undergoing CT has been evaluated as a means of preventing bacterial infectious complications and now is standard practice (Gill et al., 1992) .
At present, the new findings on KS pathogenesis have prompted investigators to study the anti-KS activity of the new antiretroviral combination therapy. HAART must be considered as a major treatment for all KS patients. Alone it may be used as first-line anti-KS therapy in the early stages of disease (T0) and/or for slowly proliferating disease (when the tumour load is low and/or the tumour growth is consistent with a long time interval to the development of HAART anti-KS activity). In patients with T1 and/or rapidly proliferating disease, the first-line treatment is chemotherapy with antiretroviral therapy followed by maintenance therapy with HAART. A study from GICAT on 53 patients of a slowly progressive disease (stage I-III according to NYU), detectable HIV-RNA viraemia and HAART naı¨ve, treated with HAART including PI as first-line treatment for KS concluded that HAART is an effective antineoplastic therapy in a high percentage of cases (overall response rate of 35%). The anti-KS activity of HAART correlates with immune restoration in patients with anti-HIV response. The complete response to HAART after partial remission following chemotherapy has convinced the GICAT investigators to perform a phase II study on the role of maintenance (M)-HAART after systemic chemotherapy in advanced (stage III-IV acc. to NYU) KS patients, HAART naive or with virological response to HAART. The results of this study indicate that HAART, in patients with good compliance to antiretroviral therapy, is an effective anti-KS therapy after debulking CT (overall response rate of 91%) . KS cells secrete angiogenic factors and cytokines that are critical for the growth and spread of KS and have been targeted for new therapeutic development as antiangiogenic agents, retinoic acids and antiviral agents. Thalidomide (40% partial response) has been shown to block TNF-a production and to inhibit basement membrane formation and intercellular adhesion molecules. Toxicities include neutropenia, depression and fever. Oral 9-cisretinoic acid (33% response rate in combination with HAART with better responses at higher CD4 þ cell count) and all-trans retinoic acid (ATRA) have been show to inhibit of IL-6 production with no apparent effect on the IL-6 receptor and to be effective in the treatment of cutaneous lesions of KS. The discovery of HHV-8 as the aetiologic agent for KS has raised the possibility of the use of antiviral agents as treatment or prophylaxis for AIDS-related KS. Interferon-a has been shown to have immunomodulatory, antiviral and antiangiogenic effects, with a 10-40% overall response rate when high doses are administered as a single agent or combined with antiretroviral therapy. Significant toxicity includes flu-like symptoms and bone marrow suppression (Levine and Tulpule, 2001 ).
Non-Hodgkin's lymphoma
The incidence of NHL among people at risk for AIDS in the United States has significantly increased since the beginning of the AIDS epidemic in 1984 and in 1986, the Centers for Disease Control recognized NHL as an AIDS-defining illness (Centers for Disease Control, 1986) . The relative risk of NHL in people with AIDS ranges between 15 for low-grade and T-cell NHL and 400 for high-grade NHL (Dal Maso and Franceschi, 2003) . However, the incidence of AIDS-related tumours has been substantially underestimated because of several factors. First, national agencies collected data on initial AIDS-defining events only. This is relevant because these tumours appear most commonly in the end stages of AIDS, when the immune system is markedly impaired. Second, most primary lymphomas of the central nervous system (CNS) are diagnosed only at the time of autopsy, and certainly many other cases of NHL outside the CNS are not diagnosed. NHLs occur among all population groups and in different countries with similar epidemiologic and clinicopathologic features. Systemic NHLs constitute 70% of all cases and the remaining 30% are primary CNS lymphomas (PCNSL) (Spina et al., 1999) . In the era preceding the introduction of HAART (pre-HAART era), NHLs represented the second most frequent cancer associated with AIDS, after KS. In contrast to KS, which predominated in homosexual individuals, NHLs distributed homogeneously throughout the spectrum of HIV risk groups (Tirelli et al., 2000) . Recently, the use of HAART has been associated with significant reductions in various opportunistic illnesses in HIV-infected patients; despite a significant reduction of KS incidence, the magnitude of reduction in the incidence of NHLs appears to be less significant, except for PCNSL. It is possible that patients treated with HAART have an improved immune function, with reduced B cells stimulation but they may survive longer, with continued B-cell stimulation and dysregulation, resulting in an increased incidence of lymphoma over time . In developing countries, the risk of HIV-associated NHL appears to be much lower than in developed countries, but earlier death from other AIDS manifestations may explain the lack of HIV-associated lymphomas in Africa (Franceschi et al., 1999) . The risk of developing lymphomas in patients with symptomatic HIV infection appears to be approximately 1.6% per year; further, the chance of developing lymphoma in patients with AIDS, alive on HAART for 3 years is estimated to be approximately 19% (Tulpule and Levine, 1999) .
AIDS-related NHL (AIDS-NHL) are characterized by a diffuse growth pattern, cellular pleomorphism, high-grade morphology and B-cell derivation. Lowgrade B-cell and T-cell NHL, which may occasionally develop in the HIV-infected population, are not considered AIDS-related tumours because their incidence has not significantly increased since the start of the AIDS epidemic. AIDS-NHL traditionally included systemic and PCNSL, but nowadays their updated clinicopathologic spectrum also comprises two novel entities, namely, primary effusion lymphoma (PEL) and plasmablastic lymphoma of the oral cavity (Spina et al., 1999a-c) . The overwhelming majority of systemic AIDS-NHL are small noncleaved-cell lymphomas (SNCCL), which include diffuse large-B-cell lymphomas (DLCL) (70%), including large noncleaved-cell lymphoma (LNCCL, 25%), immunoblastic lymphoma plasmocytoid (IBL-P, 25%) and CD30 þ anaplastic large-cell lymphoma (ALCL), which is a heterogeneous group of high-grade lymphomas at the borderline between HD and NHL (Tirelli et al., 1995a (Tirelli et al., , b, 2000 ) and Burkitt's or Burkitt-like lymphoma (30%). An intriguing pathologic characteristic common to systemic lymphomas in HIV patients is the occurrence of cases having some overlap between established histologic subtypes (Raphael et al., 1991) . The best example is represented by the so-called intermediate lymphoma, which exhibits features 'intermediate' between SNCCL and IBL-P (Carbone et al., 1995; Said, 1997) .
Recently, both in the US and Europe, a peculiar type of primary lymphomatous effusion has been recognized as an individual entity based on its distinctive biologic features and its consistent infection by a novel herpesvirus, termed HHV-8 (Cesarman et al., 1995; . Owing to its peculiar and predominant tropism for the serous cavities of the body, this type of NHL has been provisionally designated body cavity-based lymphoma (BCBL). Although BCBL exhibits an undeterminate phenotype, immunophenotypic studies have confirmed its B-cell origin. BCBL has also been termed as PEL. The overall pattern of BCBL/ PEL is a lymphoma of the serous membranes typically giving rise to lymphomatous effusions without mass formation . A particular type of lymphoma has been recently identified as a specific entity among AIDS-DLCL involving the oral cavity. This lymphoma has been designated as plasmablastic lymphoma (PBL) according to a plasmablastic morphology and immunoblastic features. The blastoid morphology and immunophenotype of these tumours indicate that they are most similar to plasmablasts, that is, cells that still have the blastoid feature of immunoblasts, but otherwise have already acquired the antigen profile of plasma cells. The clear separation of PBL from plasmacytoma is reinforced by the high rate of association of PBL with Epstein-Barr virus (EBV), whereas plasmacytomas have been rarely found to carry the genome of the virus. The real incidence of this new entity is still unknown (Delecluse et al., 1997) .
From a molecular point of view, AIDS-NHL are a heterogeneous group of malignancies. In the last few years, several studies have shown that the pathologic heterogeneity of AIDS-NHL correlates with heterogeneity of the molecular lesions associated with these lymphomas. Burkitt's lymphoma selectively associates with the activation of c-myc, whereas rearrangements of bcl-6 are restrictive to a subset of DLCL. Infection by HHV-8 clusters with BCBL/PEL; conversely, infection by EBV occurs, although at different rates, in different lymphoma types, being always associated with AIDS-PCNSL, but with a minority of systemic lymphomas. However, only immunoblastic lymphoma, included in DLCL, expresses the EBV-encoded latent membrane protein-1 (LMP-1) (Gaidano et al., 1998) .
The optimal treatment for HIV-associated NHL remains unclear; despite significant efforts to improve the outcome of AIDS-NHL, it continues to limit the life expectancy of affected individuals more significantly than any single AIDS-defining condition, except for multifocal encephalopathy. Median survival times for HIV-NHL are less than 18 months in most series in the pre-HAART era, even for patients with good prognosis characteristics. Early in the AIDS epidemic it was recognized that in addition to opportunistic infections, patients also developed lymphomas. At that time, there was no effective therapy for the underlying immune depletion resulting from the disease and prophylaxis against opportunistic infections had not yet been defined as standard practice (Little et al., 2000) .
Chemotherapy regimens similar to those used for NHL not associated with HIV infection have been used for treating patients with AIDS-NHL, with less success. With combination chemotherapy regimens of the CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)-type, CRs were obtained in 32-56% of patients (Straus, 1997) . Moreover, the use of aggressive CT in patients with HIV and NHL resulted in an increased incidence of opportunistic infections secondary to exacerbation of the immunodeficient state. A total of 20-80% of patients with HIV-related NHL treated with a variety of chemotherapeutic agents developed opportunistic infections. CT-induced myelosuppression and possible interference with monocyte-macrophage function may increase the susceptibility of these patients to opportunistic infections (Tan and Ratner, 1997) . During the pre-HAART era, preliminary phase II data for NHL in HIV-negative people have suggested better efficacy for the second-and third-generation lymphoma regimens, such as m-BACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and dexamethasone), ProMACE-CytaBOM (prednisone, doxorubicin, cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine and methotrexate with leucovorin) and MACOP-B (methotrexate with leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone and bleomycin) as compared with CHOP.
Oncologists who treated a HIV-NHL used these more complex regimens, but also recognized that patients frequently tolerated chemotherapy poorly and that CR occurred in only a minority of HIV-NHL patients and were usually of short duration (Little et al., 2000; Tirelli et al., 2002) . Efforts to improve patients' tolerance stimulated interest in the role of low-dose chemotherapy. One particularly important study in this regard was a large, randomized trial comparing standard to low-dose m-BACOD. This trial showed equivalent results in patients receiving full-and low-dose m-BACOD, with complete responses ranging from 41 to 52%, but with lower incidence of febrile neutropenia in the low-dose group. However, the incidence of opportunistic infections was equivalent in both groups and the low-dose arm was not shown to yield an improved survival outcome (Kaplan et al., 1997) . Another approach to reduce myelosuppression was the use of sargramostim (GM-CSF) associated with stan-dard-dose chemotherapy; in a small randomized trial using CHOP with or without GM-CSF, comparable treatment results were achieved with the addition of GM-CSF to CHOP as with CHOP alone, with significantly less neutropenia (Kaplan et al., 1991) . A phase I trial of m-BACOD escalated from a low-to standard-dose along with GM-CSF was conducted by the ACTG. Dose-limiting haematologic toxicity was not observed with standard doses, although other toxicities occurred (Walsh et al., 1993 ). An attempt to facilitate administration of chemotherapy was made with a trial of completely orally administered combination (lomustine, etoposide, cyclophosphamide and procarbazine), with results comparable to those obtained using other combination regimens (CR 39%, media survival of 7 months); toxicities aside from myelosuppression were mild and the costs were less than those for standarddose CHOP or m-BACOD (Remik et al., 1993) . Another trial conducted by Sparano et al. (1996) obtained promising results in the pre-HAART era, employing cyclophosphamide, doxorubicine and etoposide (CDE) as continuous infusion for 4 days along with didanosine; 58% of patients achieved a CR and the median survival was 18.4 months. Despite these results, the fact remained that the majority of patients with HIV-associated NHL did not fare well with conventional chemotherapy. For this reason, a number of investigators looked for newer therapeutic approaches. In a small study from Bologna, 12 patients with HIVassociated NHL were treated with interleukin-2 (IL-2) at dose of 6 mUI/m 2 /day by continuous intravenous infusion for 5 days for four courses along with zidovudine; 50% of patients achieved a CR and the others achieved a partial remission. Elevation in CD4, natural killer and lymphokine-activated killer cells were seen at the end of treatment (Mazza et al., 1992) . Interleukin-6 (IL-6) produced by lymphoma and surrounding cells may play a role in the growth of HIVassociated NHL and in the production of symptoms in patients, so that Emilie et al. (1994) treated 11 patients with an anti-IL-6 monoclonal antibody; five patients progressed, five had stable disease and one achieved a partial remission, but there was a clear decrease in fever and cachexia.
The treatment of HIV infection has evolved very rapidly over the past several years and there are reasons to believe that these advantages may also benefit cancer treatment in the HIV-infected patients; some lymphoma remissions have been attributed to HAART (Oksenhendler et al., 1998 , Viciana et al., 1998 . Thus, important work has been initiated in an attempt to better define the role of combined antiretroviral therapy and cytotoxic chemotherapy for AIDS-NHL. Moreover, emphasis has been given by different authors to prognostic factors. Prior to AIDS diagnosis, Karnofky Performance Status less than 70%, CD4 cell count less than 100/ml, the presence of extranodal disease, according to Kaplan are predictive of a worse outcome in AIDS-NHL patients (Kaplan et al., 1989) . Gisselbrecht et al. (1993) identified a subgroup of patients with AIDS-NHL with favourable characteristics: CD4 cell count 4100/mm 3 , histology other than immunoblastic variant of DLCL, good performance status and no prior AIDS diagnosis. Straus et al. (1998) showed that long-term survival is associated with certain pretreatment patient's characteristics, such as tumour stage I/II, CD4 cell count 4100/ml, age o35 years, no history of intravenous drug use. This study also demonstrated the utility of the International Prognostic Index (IPI) and the age-adjusted IPI for patients with HIV-associated NHL, although it was originally designed for patients with intermediate-and high-grade NHL not associated with HIV. This study had also underscored the importance of LDH levels, which is one of the parameters considered by IPI, in determining a patient's prognosis, elevated LDH levels being an adverse prognostic factor for progression-free survival in multivariate analysis. Similar findings have been reported by Vaccher et al. (1996) in a retrospective multivariate analysis, in which elevated LDH and age greater than 40 years, as well as CD4 cell counto100/ml, were independent predictors of survival in a Cox proportional-hazards analysis of patients with AIDS-NHL. The 1-year survival rate of patients with none of these adverse factors was 73% as compared with 24% for patients with one or more adverse factors.
HAART can suppress HIV viraemia to levels below the detection limits of sensitive quantitative polymerase chain reaction (PCR) essays for prolonged periods. Low viral burden is associated with increased CD4 counts and improved prognosis in HIV infection (Mellors et al., 1997) . The development of HAART has resulted in substantial improvement in the survival of patients with AIDS. More recently, the optimism has been tempered by the observation that prolonged viral suppression does not appear to be achievable in a substantial number of patients for a variety of reasons, such as the difficulty of complying with complex regimens, drug intolerance, and the developing of HIV genomic mutations conferring resistance, so that HIV eradication using current therapy is now considered to be very unlikely by many researchers, because ongoing localized HIV replication occurs even during HAART and viral reservoirs are likely to persist for a lifetime (Tirelli and Bernardi, 2001) .
One potential advantage of HAART is that viral suppression may further limit immune damage by HIV during chemotherapy and may even permit the development of antitumour immune responses. It may also reduce HIV-associated production of proinflammatory cytochines, such as IL-6, which have been proposed as a potential cofactor in lymphomagenesis in AIDS-NHL (Levine, 1993) . In addition, it is theoretically possible that in the absence of HAART, HIV could transactivate oncogenic viruses, such as HHV-8, that play a role in lymphomagenesis (Varthakavi et al., 1999) . In contrast, there is concern that overlapping toxicities and pharmacokinetic interactions between antiretroviral drugs and chemotherapy may affect the therapeutic index of the various drugs. The possibility of substantial and unexpected drug interaction is increased in the setting AIDS-related malignancies M Berretta et al of HAART, because most protease inhibitors (PI) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) are methabolized by and have substantial effects on the cytochrome P450 3A; anthracyclines, the vinca alkaloids and etoposide are metabolized via the cytocrome P450 3A too (Tan and Ratner, 1997; Little et al., 2000) . Increased toxicity may lead to a delay of chemotherapy cycles or prompt dose reduction, possibly compromising the curative potential of the lymphoma. Toxicity can also adversely affect antiretroviral therapy compliance, posing a danger of emergence of resistant HIV. Also, from a practical stand point, chemotherapy is lymphocytotoxic and can deplete CD4 cell counts by upwards of 50% independent of HIV infection, limiting the relative CD4 protective effect of antiretroviral therapy. Ultimately, the relative impact of these various factors must be balanced by considering their contribution to the lethality of lymphoma and the underlying AIDS condition (Tirelli and Bernardi, 2001; Tirelli et al., 2002) . So, many investigators have investigated and are still investigating the feasibility of concomitant administration of chemotherapy and HAART in AIDS-NHL. Ratner et al. (2001) presented preliminary data on a trial of reduced-vs standard-dose CHOP with stavudine, lamivudine and indinavir in patients with previously untreated aggressive lymphoma. The low-dose arm received 50% reduced doses of cyclophosphamide (375 mg/m 2 ), and doxorubicin (25 mg/m 2 ) with a standard dose of vincristine and prednisone; 63 patients with a median CD4 cell count of 136/mm 3 were enrolled. In all, 33% of patients in the low-dose arm and 32% of those in the standard-dose arm achieved a CR, results that are similar to those previously reported using CHOP without HAART . A total of 50% of the patients in low-dose arm had grade 3 or 4 neutropenia and 28% had hyperbilirubinaemia, whereas 28% of the patients in the full-dose arm had grade 3 or 4 neutropenia and 20% had hyperbilirubinaemia. Viral loads generally remained stable during treatment, with 77% of the patients maintaining fewer than 1000 copies of HIV-RNA/ml plasma. Pharmacokinetic analysis was performed and the findings compared with those from historical control patients not receiving anti-HIV therapy. The cyclophosphamide clearance rate was reduced to 39 ml/min/m 2 , compared with 70 ml/min/m 2 in the historical control groups, whereas the doxorubicin clearance rate was unchanged (475 vs 500 ml/min/m 2 ). Additionally, the area under the curve for indinavir was unchanged. The investigators concluded that the decreased clearance of cyclophosphamide was not associated with adverse effects and that either low-or full-dose CHOP combined with HAART could be safely and effectively administrated to patients with AIDS-NHL. Vaccher et al. (2001) have assessed the impact of HAART on CT in a matched case control retrospective analysis of 24 patients with AIDS-NHL treated with CHOP and HAART compared with 80 patients treated with CHOP or CHOP-like regimens without HAART. Antiretroviral regimens were selected based on the patient's prior therapy. Response rates were similar between the two groups. CR occurred in 50% of patients treated with CHOP-HAART and in 36% of evaluable patients treated with CT alone. Toxicity, however, was greater in the patients treated with combined therapy compared with patients treated with CHOP alone; grade 3-4 anaemia was seen in 33 and 7%, respectively, grade 3-4 neurotoxicity was observed in 17 and 0%, respectively. Leucopenia was similar between the two groups, but filgrastim (G-CSF) support was significantly higher in the CHOP-HAART group than in the control group (92 vs 63%). There appeared to be a survival advantage for patients receiving combined therapy and there was a trend for more patients receiving CHOP alone to experience opportunistic infections compared to those with combined therapy (52 vs 18%, respectively). The conclusion of the authors was that CHOP-HAART patients had a better survival than CHOP patients, suggesting that the reduction of opportunistic infections morbidity by HAART may improve the overall outcome of the combined treatment patients. In fact, in our case series of 235 patients affected by AIDS-NHL, the actuarial 3-year disease-free survival for a subgroup of 88 patients achieving CR after chemotherapy was significantly longer for those who had been treated with HAART than for the HAART-naı¨ve patients (86 vs 57%, P ¼ 0.004) (Vaccher E, data not shown). These findings have important implications for the management of AIDS-NHL; however, careful attention must be directed towards the crosstoxicity and the possible pharmacokinetic interactions of antiretroviral and antineoplastic drugs.
Concerns with the chemotherapy-HAART combined approach have been raised by a small report of 12 patients treated with combined antiretroviral therapy and CT utilizing infusional CDE þ G-CSF. In this trial, patients received saquinavir and one or two nucleoside analogue anti-HIV drugs concomitant with CDE. Severe mucositis occurred in 67% of patients treated with CDE plus saquinavir compared with 12% of patients treated on a previous trial of CDE without saquinavir. A particular concern regarding mucositis in this setting is that it can substantially impair compliance with HAART dosing (Sparano et al., 1998) . In another trial of CDE and antiretroviral therapy, plasma etoposide levels were decreased by 11-38% on CT cycles administered with didanosine, compared to cycles without didanosine (Sparano et al., 1996) . In a study conducted by the Eastern Cooperative Oncology Group (ECOG), the efficacy of CDE and didanosine monotherapy was evaluated ; in this study, 48 patients received continuous didanosine with up to 8 monthly cycles of CDE and G-CSF and intrathecal cytarabine if the bone marrow was positive and the histology was small noncleaved-cell lymphoma. Overall, 46% achieved a CR. The median time to progression was 14.9 months, median survival was 8.2 months and survival at 1 year was 48%. The role of dose intensity and antiretroviral therapy remains unclear in AIDS-NHL. A method to investigate this relationship partially has been given by Tirelli and the European Intergroup Study of HIV-NHL . In this study, patients were randomized into stratified groups based on the number of adverse prognostic factors defined as the presence or absence of prior AIDS-defining events, CD4 cell count o100/mm 3 and performance status score greater than 1. Patients with no adverse prognostic factors were defined as low risk and were randomized to receive either the intensive ACBVP regimen (doxorubicin, cyclophosphamide, vindesine, and prednisolone) (80 patients) or CHOP regimen (79 patients). All patients received G-CSF support. Complete responses were seen in 66 and 60% of patients treated with ACBVP and CHOP, respectively. Survival was similar in both groups. Patients with at least one adverse prognostic factor were included in the intermediate-risk disease and were randomized to receive either full-dose CHOP (59 patients) or 50% dosereduced CHOP (51 patients). The complete response rate was 63% for the full-dose arm and 39% for the half-dose arm. However, the improved response rate did not significantly affect overall survival because of a relapse and death from AIDS progression, confirming the need for more effective treatments for both lymphoma and the underlying immunosuppression.
Another important area of investigation is the role of CNS prophylaxis in AIDS-NHL. In HIV-negative patients, CNS prophylaxis is usually limited to patients with Burkitt's lymphoma and DLCL with multiple extranodal disease sites such as the bone marrow (van Besien et al., 1998). However, routine CNS prophylaxis is now considered standard practice in HIV-NHL, based on the findings of a high percentage (15-20%) of patients with CNS involvement at presentation (Levine, 1991) . Some investigators have questioned the routine use of intrathecal prophylaxis in cases with intermediate-grade histology and uninvolved bone marrow. This was based on a series of 26 patients who did not receive CNS prophylaxis, of whom none developed isolated CNS disease (Deasi et al., 1999) . However, CNS progression is an important cause of both morbidity and mortality, and as treatments improve, CNS relapse may become a relatively more important issue; thus, many authors continue to believe that CNS prophylaxis with intrathecal methotrexate or cytarabine is a useful adjunct for all patients with AIDS-NHL and its omission has to be best explored in many research settings (Little et al., 2000) .
There exist no standard options for the treatment of relapsed or refractory disease, but two publications suggest that second-line chemotherapy can be beneficial. One regimen combined etoposide with continuous infusion ifosfamide and mesna; although the first 14 of the 27 reported patients were treated on a dose escalation trial, the overall response rate was 59%, with 42% achieving a CR and 17% achieving partial remission. In those treated at the higher dose level, the CR rate was 62%. The median duration of response was 12.5 weeks (range 4-78 weeks), with a median survival of 16 weeks (range 2-168 weeks) . Our group found that second-line chemotherapy with etoposide, mitoxantrone and prednimustine can be beneficial . Gabarre et al. (1996) have reported the case of a man with relapsed AIDS-NHL, successfully treated with ESHAP (etoposide, methylprednisolone, cytarabine and cisplatine) chemotherapy followed by BEAM (BCNU, cytarabine, etoposide, melphalan) high-dose chemotherapy and autologous bone marrow transplantation (ABMT) in the pre-HAART era. The patients achieved CR, but he experienced many opportunistic complications, such as atypical Mycobacteria pneumonia, intestinal cryptosporidiosis, CMV retinitis and colitis, due to the high immunosuppression state (Gabarre et al., 1996) . The introduction of HAART, by restoring the immune system defect in HIV patients has allowed the exploration of more dose-intensive therapy such as ABMT in selected patients with AIDS-NHL. Molina et al. (2000) reported two cases of patients with AIDS-NHL successfully treated with high-dose chemotherapy followed by ABMT; both patients were receiving HAART during chemotherapy. G-CSF was employed for CD34 þ peripheral blood stem cells (PBSC) mobilization and prompt haematopoietic recovery was observed after ABMT. Both patients achieved a durable CR from their lymphoma. The authors concluded that ABMT is feasible in patients with AIDS-NHL. Gabarre et al. (2000) have recently reported eight cases of patients with HIV and lymphoma (both NHL and HD) treated with ABMT. Four patients died (one of opportunistic infection, the others of disease progression), but four are alive and in CR from their lymphoma. All patients except one have received HAART during the treatment. The authors conclude that collection and grafting of stem cells is feasible and seems appropriate in CT-sensitive HIV-1-associated lymphoma (Gabarre et al., 2000) . Krishnan et al. (2001) reported the cases of nine patients with HIV and HD or NHL, who mobilized a median of 10.6 Â 10 6 CD34 þ cells/kg and engrafted after ABMT. CD4 counts recovered to pretransplantation levels and HIV viral loads (VL) were controlled in patients compliant with HAART; seven of nine patients remained in remission from their lymphoma at a median of 19 months after transplantation. Six patients had a rise in their HIV VL in the first month following the transplantation, whereas three patients maintained an undetectable VL. In five of the seven evaluable patients, HIV VL was undetectable at 12 months from transplantation. The authors concluded that patients with AIDS-NHL on HAART can engraft following ABMT; prolonged lymphoma remissions without significant compromise of immune function can be seen. Re et al. (2002) have started a programme of PBSC mobilization and collection with subsequent high-dose chemotherapy and transplantation as salvage therapy for patients with relapsed or refractory HIV lymphomas. In all, 10 patients were enrolled, seven with HD and three with NHL. All patients were on HAART. After a median of three aphaeresis, a median of 5.9 (range 4.1-8.3) Â 10 6 / kg CD34 þ cells were collected after cyclophosphamide 4 g/m 2 þ G-CSF in two or G-CSF-supported standarddose chemotherapy in five cases. Six patients underwent high-dose chemotherapy with BEAM and ABMT.
Prompt haematologic recovery was observed in all patients. Treatment-related toxicities included two WHO three and one WHO two oral mucositis and one WHO three reaction to DMSO. Infectious complications during neutropenia included one facial cellulites, one S. epidermidis sepsis and two Clostridium colitis; all patients responded to treatment. HIV VL remained undetectable in patients receiving HAART before and after ABMT. No HCV reactivations were seen. Five/six patients achieved CR and three were alive and disease free at 2, 3 and 9 months from ABMT. The authors concluded that adequate number of CD34 þ cells can be collected in most patients with AIDS-NHL even after intensive first-line chemotherapy and high-dose chemotherapy with ABMT is feasible, with rapid haematologic recovery and acceptable toxicity. Interest has also been generated in the potential role of anti-CD20 monoclonal antibody, rituximab, in HIV-NHL. When rituximab is used alone in relapsed lymphomas, it has activity, yet there is particular interest in exploring its activity in combination with chemotherapy, based on evidence that it is well tolerated and effective (Little et al., 2000) . Spina et al. (2003) report the results of a trial in which 41 patients with AIDS-NHL CD20 positive were enrolled; the patients received a combination of rituximab þ CT with CDE every 4 weeks for up to six cycles; HAART was given concomitantly. In all, 38 patients were evaluable for response and toxicity; 76% achieved CR, 5% had partial remission and seven patients progressed. With a median follow-up of 12 months, only three patients out of 29 complete responders (10%) had relapsed and 32 out of 41 patients are alive. Grade 3-4 neutropenia, anaemia and thrombocytopenia were observed in 80, 37 and 29% of the patients, respectively. The authors concluded that the combination of rituximab plus CDE seems to be very active, with a CR rate of 76%, much higher than that reported so far in AIDS-NHL (45-65%), also with a significant increase of overall survival (70% at 2 years vs a median of 7-18 months), so the association of rituximab þ CT should be strongly recommended as a front line treatment for patients with CD20 þ NHL and HIV.
Hodgkin's disease
HD is the most common non-AIDS defining tumour among HIV-infected individuals.
The majority of recent studies demonstrate an increased incidence of HD in HIV-infected individuals. In particular, data from AIDS cohort and registry matching studies showed a relative risk of HD in the HIV setting ranging from 2.5 to 8.5 (Franceschi et al., 1998; Spina et al., 1999a-c) .
Thus, an association between HD and HIV infection seems to be well established, although with a relative much lower than that for NHL (IARC, 1996) .
Although the majority of the evidence suggests that HD may be more common in HIV-infected intravenous drug users than in other groups at risk for HIV, there does not appear to be a restriction of the disease to this group alone (Rubio, 1994; Koblin et al., 1978) .
Recently, Franceschi et al. (1998) reported a relative risk of 7.9 in a European series from Italy.
Whether this evidence is sufficient to consider HD, an AIDS-defining illness, remains a matter of controversy.
The histological diagnosis of HD is still based on the presence of classical Reed-Sternberg (RS) cells in an appropriate cellular background. HD occurring in the HIV population exhibits pathological features that are different from those of HD in the general population (Harris et al., 1994) . In fact, the distribution of HD subtypes in the HIV population is characterized by the predominance of unfavourable histological subtypes, and mixed cellularity is the most frequently diagnosed subtype (Tirelli et al., 1995a, b) .
A high frequency of EBV association has been shown in HD tissue from HIV population (Boiocchi et al., 1993) . The EBV genomes in such cases have been reported to be episomal and clonal, even when detected in multiple independent lesions.
On the other hand, EBV association with HD occurring in HIV-uninfected population have been shown to be globally lower than 50%, although a higher association of EBV has been found with mixed cellularity subtype.
One of the most peculiar features of HD in the HIV population is the widespread extent of the disease at presentation and the frequency of systemic 'B' symptoms, including fever, night sweats and/or weight loss 410% of the normal body weight (70-96% of patients).
Around 75% of patients had advanced disease stages (stage III-IV according to Ann Arbor staging classification) with a frequent involvement of extra nodal sites, and the most common being the bone marrow, liver and spleen. Bone marrow involvement occurs in 40-50% of patients, and may be the first indication of the presence of HD in 20% of cases (Ree et al., 1991; Rubio, 1994; Errante et al., 1994; Tirelli et al., 1995a, b) .
HD as Burkitt's-type NHL tend to develop as an earlier manifestation of HIV infection with a higher median CD4 cell count (around 300/mm 3 ), than HIV diffuse large-cell lymphoma (Andrieu et al., 1993; Rubio, 1994; Tirelli et al., 1995a, b) .
Staging evaluation of patients should include a bone marrow biopsy, CT scan of the chest, abdomen and pelvis, and other tests as clinically indicated.
Optimal therapy for HD in the HIV population has not been defined yet. As most patients had advanced disease, they were treated with combination chemotherapy regimens, that is, MOPP (mechlorethamine, vincristine, procarbazine and dacarbazine), and more recently with ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine), but the CR rate remains lower than that of HD in the general population. Moreover, the therapy of HD-HIV population presents many problems. The main one is represented by immunosuppression induced by antineoplastic treatment that can further compromise the immunocellular deficit of HIV-infected patients, and can facilitate the onset of opportunistic infections and/ or the evolution of HIV infection itself. Furthermore, although CD4 þ cell counts in these patients are usually normal or slightly decreased at diagnosis, they may become severely depressed during and after treatment, leading to a higher susceptibility to opportunistic infections. Finally, leucopenia, frequently present in patients with HIV-HD due to previous therapy with nucleoside analogues and/or to HIV-related myelodysplasia, sometimes makes conventional dosage of CT difficult to administer. Retrospective evaluations of therapy reported in the literature have revealed that the CR rate (range 46-65%) is far below that reported in patients with HD without HIV infection, with a median survival of one year and the 2-year disease-free survival rate of 50% Errante et al., 1994 Errante et al., , 1999 .
We reported the results of a prospective nonrandomized trial with epirubicin, bleomycin, vinblastine and prednisone (EBVP) chemotherapy in combination with antiretroviral therapy primary use of G-CSF, and Pneumocystis carinii pneumonia (PCP) prophylaxis in 35 previously untreated patients with HD and HIV. The majority of patients (83%) had advanced stages of HD at diagnosis, 26% of the patients had an AIDS diagnosis for opportunistic infection before the onset of HD and 90% had B symptoms. An overall response rate of 91% was observed with a CR rate of 74%. The toxicity was moderate, with a grade 3-4 leucopenia and thrombocytopenia of 32 and 10%, respectively. Of 26, 10 (38%) patients who had achieved a CR relapsed. In all, 23 patients died of HD progression alone or in association with opportunistic infections, the cause of death in 48 and 9% of patients, respectively. The median survival was 16 months, with a survival rate of 32% and a disease-free survival of 53% at 36 months (Errante et al., 1999) . The ACTG reported the results of a phase II study in 21 patients treated with ABVD chemotherapy for four to six cycles and primary use of G-CSF. Antiretroviral therapy was not used during the treatment, but it was started at the end of chemotherapy. The vast majority (90%) of patients had systemic 'B' symptoms at diagnosis and 67% had stage IV disease. The CR rate, on an intent-to-treat analysis, was 42% with an overall objective response rate of 62%. Median survival for all patients was 18 months (Levine et al., 2000) .
Recently, Horning et al. (2002) reported the results of a prospective phase II study using Stanford V regimen (doxorubicin, vinblastine mecloretamine, etoposide, vincristine, bleomycine and prednisone) consisting of short-term chemotherapy (12 weeks) with adjuvant radiotherapy, in HIV-negative patients with locally extensive and advanced HD. In unfavourable HD, high CR rate and disease-free survival rate have been shown.
GICAT data show that Stanford V regimen with concomitant HAART is feasible and highly active in the setting of HIV-related HD. Furthermore, the concomitant use of HAART does not seem to increase chemotherapy toxicity. In conclusion, the outcome of patients with HIV-associated HD should be improved with better combined antineoplastic and retroviral approaches. The results of these studies are summarized in Table 1 .
In the HAART era, new therapeutic strategies need to be explored, such as high-dose chemotherapy, concomitant with antiretroviral therapy, autologous stem cell transplantation should be used to improve the response rate and disease-free survival of these patients.
Anogenital malignancies

Cervical cancer
In the early years of the AIDS epidemic in the United States, relatively few women were diagnosed with cervical cancer. Cervical intraepithelial neoplasia (CIN) has been increasingly diagnosed in HIV-infected women (Maiman et al., 1990; Mandelblatt et al., 1992; Fructher et al., 1994; Klein et al., 1994; Wright et al., 1994) and invasive cervical cancer (ICC) is currently considered an AIDS-defining condition (Centers for Disease Control, 1993a) . CIN in HIV-infected women is usually associated with high-grade histology (CIN Table 1 EBVP Errante et al. (1999) ABVD Levine et al. (2000) Stanford V Spina et al. (2002) No patients (Penn, 1986) . Furthermore, other risk factors such as multiple sexual partners, early parity, early coitarche, cigarette smoking, sexually transmitted disease are often present in these women. The molecular mechanism for the pathogenesis of cervical carcinoma in both HIV-infected and -uninfected women is incompletely understood. However, both viral and cellular factors appear to be involved. A strong and cellular factors appear to be involved. A strong epidemiological association exists between several types of HPV (subtype 16, 18, 31, 33 and 35) and cervical carcinoma. This risk is particularly elevated in woman with AIDS who have a higher incidence of coinfection by HPV and who may lack sufficient immune surveillance of HPV infection owing to HIV-associated T-cell immunodeficiencies. HPV integration into host DNA alters the viral E1/E2 genes, allowing uncontrolled expression of the E6/E7 transforming genes. Increased expression of E6 and E7 oncoproteins that bind the products of the tumour suppressor genes, may contribute to malignant transformation (Laimons, 1993) . Squamous neoplasia of the cervix is best understood as a continuum of a single disease approach. This continuum is histologically represented as a progression of changes beginning with CIN1 (mild displasia), followed by CIN2 (moderate displasia) and CIN3 (severe displasia), and eventually resulting in invasive cervical cancer. These histologic changes are thought to regenerate at the squamocolumnar epithelial junctions, because these cells are likely to be the most vulnerable to environmental neoplastic/oncogenic stimuli, including HPV infection. The histological changes associated with HPV including koilocytosis, multinucleation and increased mitoses may, in fact, be indistinguishable from early CIN. The median time of progression of CIN1 to CIN3 is approximately seven years (Barron and Richart, 1971) , whereas the development of invasive carcinoma from CIN3 may require an additional 5-7 years (Kolstad and Klem, 1976; McIndoe et al., 1984) . The degree of immunosuppression appears to be related to the occurrence and severity of CIN as well. In fact, CIN is more common in symptomatic or severely CD4-depleted patients and appear to be at highest risk for the development of ICC.
In 1993, the CDC recommended annual Papanicolau smears for HIV-infected women who have had two successive adequate and normal smears more than 6 months apart (Centers for Disease Control, 1993b). However, many clinicians have opted to perform semiannual or more frequent Pap testing with or without colposcopy. The rationale for this approach includes the fact that HIV-infected women are usually being seen in the health-care system more often than once a year for other reasons, and the high rate of inflammation that may obscure a small lesion and the high incidence of concurrent vulvar, vaginal and anal neoplasia seen in this group. It seems prudent to recommend a low threshold for performing Pap smear and colposcopy in HIV-infected women until the limitations of traditional screening strategies are better understood. A thorough annual examination including visual inspection of the anus, vulva and vagina, as well as Pap smear and screening colposcopy should be considered the minimal appropriate evaluation of the lower tract in these patients.
Standard treatments for CIN have utilized excisional or ablative techniques and include cryosurgery, laser ablation, loop electrosurgical excision procedure (LEEP) excision and cone biopsy.
Observation of early lesions for a period of 3-6 months may also be appropriate, because early CIN may regress spontaneously and is unlikely to progress to invasive disease.
Overall, current treatment strategies for CIN appear to be less effective in HIV-infected women than in historical populations of unknown, but presumed HIVnegative serostatus. The more severely imunosuppressed women (CD4 cell count o500/ml) are most likely to develop recurrent disease, but even those with CD4 count 4500 ml have higher recurrence rates than non-HIV-infected women. The increase in recurrence rate seems to occur with all standard techniques, although it seems more frequent with cryotherapy. Loop excision may be most appropriate for HIV-infected patients because it eliminates the risk of vapourizing a small invasive cancer, which may be more likely in HIVinfected patients owing to the more aggressive course and because the cost in time and money compares favourably with that for cone biopsy.
Therapeutic recommendations for HIV-infected women with invasive cervical cancer should be the same as for non-HIV-infected women, because most HIVinfected women will die from cervical cancer rather than from other AIDS-related disease. In addition, it appears that elective gynaecologic surgery may be undertaken in asymptomatic HIV-infected women with no greater risk of complications than in non-infected women. As with any serious illness, it is appropriate to counsel the patients regarding the aggressive nature and poor prognosis of cervical cancer in this setting. Until now, gynaecologists played a relatively small part in the evaluation and treatment of women with HIV infection. However, as improvements in the treatment of other HIV-related illness and HIV infection itself increase life expectancy, and the number of infected women rises, more attention is being paid to traditional gynaecologic issues such as sexually transmitted disease and genital neoplasms. It is hoped that gynaecologists, serving as primary advocates for women's health care, can play a leading role in developing innovative investigational strategies for HIV-related diseases.
Anal cancer
There is strong evidence of a relationship between HIVinduced immunodeficiency, HPV infection and the development of anal intraepithelial neoplasia (AIN) (Frazer et al., 1986; Carter et al., 1995) also termed squamous intraepithelial lesion (SIL). Patients with HIV infection are more likely to have both HPV infection AIDS-related malignancies M Berretta et al and AIN than are non-HIV infected persons with similar demographic characteristics. Moreover, AIN is more common among HIV-infected persons with low CD4 cell count and more advanced clinical stage of HIV disease. The incidence of anal cancer in men with a history of receptive anal intercourse has been estimated to be 35 per 100 000 person year, prior to the AIDS epidemic (Daling et al., 1987; Biggar and Rabkin, 1996) . Recent estimates of incidence rates of anal cancer in HIV-positive men may be about twice that of HIV-negative homosexual men (Biggar and Rabkin, 1996) .
A history of receptive anal intercourse, genital condylomata, other sexually transmitted diseases and persistence of HPV infection are associated with increased risk of anal cancer in HIV-infected individuals, similarly as in HIV-negative persons (Northfelt et al., 1996 , Goedert et al., 1998 . Specific types of HPV, such as six and 11 have been associated with low-grade SIL (LSIL) that rarely progresses to invasive cancer. HPV types 16 and 18 are associated with invasive anogenital cancers and the lesions with the potential to progress to invasive cancer, such as anal or cervical high-grade (HSIL) (Palefsky and Holly, 1995) . Several different cohorts of HIV-positive and HIV-negative homosexual men have been observed, primarily in San Francisco, CA, and Seattle, WA, USA. These data were collected mostly before the introduction of HAART. Results from cross-sectional analyses of the prevalence of anal HPV infection have shown that anal HPV infection is found in nearly all HIV-positive men as well as a substantial proportion of HIV-negative homosexual men (Palefsky et al., 1991 (Palefsky et al., , 1997 . In one recent study in San Francisco, 93% of the HIV-positive men and 61% of the HIV-negative men had anal HPV infection detected by PCR. Infection with multiple types of HPV was more frequent in the HIV-positive men compared with the HIV-negative men and was more common in those with lower CD4 cell counts. Consistent with the HPV infection data, the prevalence of anal squamous intraepithelial lesions (ASIL) was also higher among HIV-positive homosexual men than HIVnegative homosexual men, particularly those with lower CD4 cell counts (Melbye et al., 1996) . LSIL and HSIL were present in 36% of HIV-positive men and 7% of HIV-negative men. The relative risk of ASIL inversely correlated with CD4 cell counts and compared with HIV-negative men was 3.8 for those with CD4 counts 4500 cells/mm 3 and 7.3 for those with CD4 counts o200 cells/mm 3 . The impact of HAART on the natural history of ASIL is not yet known (Palefsky, 1998) . It is possible that successful suppression of HIV replication by HAART will be accompanied by restitution of immune response to HPV and regression of HSIL to LSIL or normal. However, early data suggest that most cases of HSIL will not regress after initiation of HAART (Palefsky, 2000) .
Given the success of the Pap-smear screening programme in reducing the incidence of cervical cancer, it is likely that a similar approach in identifying and treating persons with HSIL is justified. Data from literature support the use of anal cytology as a screening test for detection of ASIL (Palefsky et al., 1998a) as well as the use of anoscopy to detect HSIL and distinguish it from LSIL (Palefsky et al., 1998b) . A recent cost-effective analysis published by Goldie et al. (1999) demonstrated that such screening programme are comparable in cost to other preventative measures accepted as standard of care for HIV-infected persons.
Treatment of anal dysplasia in HIV-infected persons is controversial. Low-grade lesions can be followed clinically with serial anoscopy and biopsy, while high-grade lesions, when immune function is still preserved, can be treated with surgical excision and laser ablation if the dysplasia is limited. Those with extensive disease or advanced immunosuppression can be managed with close clinical follow-up and biopsy of any suspicious lesions.
Anal cancer is very sensitive to chemotherapy and radiotherapy, being a highly curable cancer. In the general population, the overall rate of long-term survival with any preservative approach is 65-75%. Recent data suggest that HIV-infected patients with anal cancer should be treated with the same approach as HIV-negative individuals (Peddada et al., 1997) . In association with HAART, an aggressive approach to the treatment of anal cancer in HIVinfected patients is warranted. Patients with CD4 cell counts less than 200/ml may experience considerable toxicities, but the majority will have their disease controlled with standard therapy. Patients with CD4 cell counts greater than 200/mm 3 seem to have less treatment-related morbidity and excellent clinical outcomes (Hoffman et al., 1999) .
Other tumors
As the AIDS epidemic advances, other tumours are being increasingly recognized in HIV-infected individuals including skin cancer, testicular cancer, lung cancer, and head and neck tumours.
HIV-infected patients are at increased risk for the development of cutaneous neoplasm. Basal cell carcinoma is likely seen in increased incidence in HIV-infected individuals (Lobo et al., 1992) . These tumours are mostly superficial, multicentric and located on the trunk. Of interest is the association between the degree of immunosuppression and the number of cutaneous neoplasm or the recurrence of squamous cell carcinoma. Although there have been more than 120 reported cases of lung cancer in HIV-infected patients, epidemiological data do not support the existence of an increased risk for development of this tumour in an HIV setting. Many features of lung cancer in HIV-infected individuals differ from the disease in the general population. Adenocarcinoma predominates as histological subtype; this feature differs from the usual distribution of tumour type in most lung cancer series of the general population, where adenocarcinoma, squamous cell and small-cell carcinoma each account for approximately one-third of the cases. Overall, tobacco smoking appears to be the major carcinogenic agent in HIV-infected patients, being present in more than 90% of cases as in the general population. More than 70% of HIV-infected patients present with advanced stages or inoperable disease, including 55% with metastases at the time of diagnosis (Spina et al., 1999a-c) . Diagnosis of lung cancer may be delayed in HIV-infected patients, because signs and symptoms of the disease may be similar to those of common pulmonary opportunistic infections. The survival of patients with lung cancer and HIV infection is very poor, with a median survival of around 6 months and with 10% of survivors at 1 year from diagnosis. As regards the management of patients with lung cancer and HIV infection, we believe that they can be approached with the same therapeutical strategies as in the general population, if HIV seropositive homosexual men have a significant increase in the incidence of testicular cancer as compared to data of the general population (Lyter et al., 1998) . The median CD4 cell count of 260/ml reported in an Italian series of 26 patients affected by germ cell testicular cancer is not directly related to the level of immune function (Bernardi et al., 1995) . The majority of HIV-infected patients with germ cell tumours tolerate standard therapy and obtain a cure rate similar to that of HIVinfected patients. Survival of HIV-infected patients with testicular tumours closely parallels the natural history of HIV disease. A 1 year of survival is not different from that reported for HIV-infected patients without testicular tumours with a similar CD4 cell count. Therefore, patients with HIV infection affected by testicular cancer should be offered the standard therapeutical approach, since the majority can be cured of their tumours and have a good quality of life. Attention should be paid to effective therapeutical options for the underlying HIV infection and for opportunistic infections prophylaxis.
Conclusions
The spectrum of cancers in patients with HIV infection may further develop since these patients survive longer with HAART and with a better control of opportunistic infections. Several questions such as feasibility and toxicity, drug-drug interactions face the oncologists using the combination of HAART and chemotherapy for the management of patients with malignancies and HIV infection. With the increasing use of HAART, the dilemma is of instituting or continuing protease inhibitors use while chemotherapy is started. Most clinicians would recommend continuation of HAART until unacceptable toxicity occurs. Based on the advances in our understanding of HIV viral dynamics and the availability of newer antiretroviral therapies, the choice for anti-HIV agents in patients receiving CT is important . Continuation of HAART with prophylaxis against opportunistic infections in patients receiving CT may be beneficial. With recent data emerging on the role of HIV in oncogenesis, the use of HAART may improve the treatment outcomes of patients with HIV infection and malignancy.
